{"id":"W4382807702","doi":"10.1016/j.annonc.2023.04.015","title":"LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"ca_institutions":"North York General Hospital","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; Astellas Pharma; Eisai; Foundation Medicine; MacroGenics; Array BioPharma; Ipsen; BeiGene; Halozyme; Mirati Therapeutics; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Incyte; Taiho Pharmaceutical; Ludwig Institute for Cancer Research; Exelixis; Sanofi; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline; Amgen","keywords":"Pembrolizumab; Medicine; Lenvatinib; Microsatellite instability; Colorectal cancer; Oncology; Internal medicine; Regorafenib; DNA mismatch repair; Standard of care; Cancer; Immunotherapy; Microsatellite","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001479978,0.001225082,0.001722249,0.0004036772,0.0003245141,0.001283568,0.000995782,0.00122597,0.004829579],"category_scores_gemma":[0.001227184,0.000478627,0.002539235,0.0003836917,0.0007019854,0.001122005,0.0004058729,0.004583286,0.001012229],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001335531,"about_ca_system_score_gemma":0.001110488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001736534,"about_ca_topic_score_gemma":0.005093152,"domain_scores_codex":[0.9995412,0.0002542949,0.00001586616,0.00006118865,0.00004015051,0.00008741062],"domain_scores_gemma":[0.9993634,0.000175615,0.0001283898,0.00004120659,0.00003344987,0.0002579067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8454415,0.01987227,0.003475553,0.001764301,0.006076257,0.0001520271,0.000140843,0.003545988,0.005616498,0.0006811525,0.007690076,0.1055434],"study_design_scores_gemma":[0.7607779,0.2138102,0.01300201,0.0001750652,0.002748397,0.0002354081,0.00012516,0.002722119,0.00107672,0.0006864876,0.0045892,0.00005127885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979216,0.009336599,0.0005805201,0.001637114,0.0005438348,0.001173463,0.002047021,0.0001589579,0.005306535],"genre_scores_gemma":[0.9825345,0.004421792,0.001296587,0.002366734,0.0003167364,0.001310126,0.002760517,0.00004068293,0.004952527],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004829579,"threshold_uncertainty_score":0.01615655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1698214086617726,"score_gpt":0.4817881493281347,"score_spread":0.3119667406663621,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}